Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.
Thépot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, Delaunay J, Cluzeau T, Marfaing Koka A, Stamatoullas A, Chaury MP, Dartigeas C, Cheze S, Banos A, Morel P, Plantier I, Taksin AL, Marolleau JP, Pautas C, Thomas X, Isnard F, Beve B, Chait Y, Guerci A, Vey N, Dreyfus F, Ades L, Ifrah N, Dombret H, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies (GFM), Acute Leukemia French Association (ALFA); Groupe Ouest-Est des Leucémies Aiguës; Maladies du Sang (GOELAMS). Thépot S, et al. Among authors: dartigeas c. Am J Hematol. 2014 Apr;89(4):410-6. doi: 10.1002/ajh.23654. Epub 2014 Feb 6. Am J Hematol. 2014. PMID: 24375487 Free article.
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).
Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Sorin L, Dreyfus F, Cluzeau T, Delaunay J, Sanhes L, Eclache V, Dartigeas C, Turlure P, Harel S, Salanoubat C, Kiladjian JJ, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM). Thepot S, et al. Among authors: dartigeas c. Blood. 2010 Nov 11;116(19):3735-42. doi: 10.1182/blood-2010-03-274811. Epub 2010 Jul 27. Blood. 2010. PMID: 20664061 Free article. Clinical Trial.
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.
Itzykson R, Thépot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Salanoubat C, Visanica S, Stamatoullas A, Isnard F, Marfaing-Koka A, de Botton S, Chelghoum Y, Taksin AL, Plantier I, Ame S, Boehrer S, Gardin C, Beach CL, Adès L, Fenaux P; Groupe Francophone des Myelodysplasies(GFM). Itzykson R, et al. Among authors: dartigeas c. Blood. 2011 Jan 13;117(2):403-11. doi: 10.1182/blood-2010-06-289280. Epub 2010 Oct 12. Blood. 2011. PMID: 20940414 Free article. Clinical Trial.
Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG. Leblond V, et al. Among authors: dartigeas c. J Clin Oncol. 2013 Jan 20;31(3):301-7. doi: 10.1200/JCO.2012.44.7920. Epub 2012 Dec 10. J Clin Oncol. 2013. PMID: 23233721 Clinical Trial.
The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.
Lamarque M, Raynaud S, Itzykson R, Thepot S, Quesnel B, Dreyfus F, Rauzy OB, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Visanica S, Stamatoullas A, Fenaux P, Adès L. Lamarque M, et al. Among authors: dartigeas c. Blood. 2012 Dec 13;120(25):5084-5. doi: 10.1182/blood-2012-09-453555. Blood. 2012. PMID: 23243156 Free article. No abstract available.
Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).
Bally C, Thépot S, Quesnel B, Vey N, Dreyfus F, Fadlallah J, Turlure P, de Botton S, Dartigeas C, de Renzis B, Itzykson R, Fenaux P, Adès L. Bally C, et al. Among authors: dartigeas c. Leuk Res. 2013 Jun;37(6):637-40. doi: 10.1016/j.leukres.2013.02.014. Epub 2013 Mar 15. Leuk Res. 2013. PMID: 23499498 Clinical Trial.
Azacitidine for the treatment of relapsed and refractory AML in older patients.
Itzykson R, Thépot S, Berthon C, Delaunay J, Bouscary D, Cluzeau T, Turlure P, Prébet T, Dartigeas C, Marolleau JP, Recher C, Plantier I, Stamatoullas A, Devidas A, Taksin AL, Guièze R, Caillot D, Vey N, Adès L, Ifrah N, Dombret H, Fenaux P, Gardin C. Itzykson R, et al. Among authors: dartigeas c. Leuk Res. 2015 Feb;39(2):124-30. doi: 10.1016/j.leukres.2014.11.009. Epub 2014 Nov 24. Leuk Res. 2015. PMID: 25524177 Clinical Trial.
A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.
Leblond V, Morel P, Dilhuidy MS, Leleu X, Soussain C, Leprête S, Dreyfus B, Dartigeas C, Mahé B, Anglaret B, Pégourié B, Besson C, Aurran T, Vekhoff A, Tournilhac O, Banos A, Oya H, Lejeune J, Ouzegdouh M, Chevret S; French Innovative Leukemia Organization (FILO). Leblond V, et al. Among authors: dartigeas c. Leuk Lymphoma. 2017 Nov;58(11):2615-2623. doi: 10.1080/10428194.2017.1307357. Epub 2017 Apr 10. Leuk Lymphoma. 2017. PMID: 28395585 Clinical Trial.
Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).
Godet S, Protin C, Dupuis J, Dartigeas C, Bastie JN, Herbaux C, Leblond V, de Guibert S, Ghez D, Brion A, Ysebaert L, Delmer A, Quinquenel A. Godet S, et al. Among authors: dartigeas c. Am J Hematol. 2018 Feb;93(2):E52-E54. doi: 10.1002/ajh.24981. Epub 2017 Dec 4. Am J Hematol. 2018. PMID: 29164674 Free article. No abstract available.
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Michallet AS, Dilhuydy MS, Subtil F, Rouille V, Mahe B, Laribi K, Villemagne B, Salles G, Tournilhac O, Delmer A, Portois C, Pegourie B, Leblond V, Tomowiak C, de Guibert S, Orsini F, Banos A, Carassou P, Cartron G, Fornecker LM, Ysebaert L, Dartigeas C, Truchan Graczyk M, Vilque JP, Aurran T, Cymbalista F, Lepretre S, Lévy V, Nguyen-Khac F, Le Garff-Tavernier M, Aanei C, Ticchioni M, Letestu R, Feugier P. Michallet AS, et al. Among authors: dartigeas c. Lancet Haematol. 2019 Sep;6(9):e470-e479. doi: 10.1016/S2352-3026(19)30113-9. Epub 2019 Jul 16. Lancet Haematol. 2019. PMID: 31324600 Clinical Trial.
56 results